Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: sigilon.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/23/2021 | $12.00 → $7.00 | Buy | Canaccord Genuity |
12/1/2021 | $16.00 → $7.00 | Overweight | Barclays |
11/30/2021 | $9.00 → $4.50 | Equal-Weight | Morgan Stanley |
11/30/2021 | $15.00 → $4.00 | Buy → Hold | Jefferies |
10/29/2021 | $14.00 | Buy | BTIG |
8/2/2021 | $15.00 | Buy | Jefferies |
7/19/2021 | $62.00 → $43.00 | Buy | Canaccord Genuity |
7/16/2021 | $45.00 → $9.00 | Equal-Weight | Morgan Stanley |
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $7.00 from $12.00 previously
Barclays reiterated coverage of Sigilon Therapeutics with a rating of Overweight and set a new price target of $7.00 from $16.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $4.50 from $9.00 previously
Jefferies downgraded Sigilon Therapeutics from Buy to Hold and set a new price target of $4.00 from $15.00 previously
BTIG initiated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $14.00
Jefferies resumed coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $15.00
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $43.00 from $62.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $9.00 from $45.00 previously
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
15-12G - Sigilon Therapeutics, Inc. (0001821323) (Filer)
EFFECT - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
S-8 POS - Sigilon Therapeutics, Inc. (0001821323) (Filer)
POS AM - Sigilon Therapeutics, Inc. (0001821323) (Filer)
8-K - Sigilon Therapeutics, Inc. (0001821323) (Filer)
25-NSE - Sigilon Therapeutics, Inc. (0001821323) (Subject)
SC TO-T/A - Sigilon Therapeutics, Inc. (0001821323) (Subject)